New imaging test could spot rare childhood disease sooner
NCT ID NCT04943211
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to improve how doctors diagnose and monitor histiocytosis, a rare disease that causes abnormal cell growth, in children under 18. Researchers will use a special imaging agent called fluorodeoxyglucose (18F-FDG) in PET-CT scans, along with genetic testing of tumor tissue and blood. The goal is to see how well these methods track the disease over time, potentially leading to earlier detection and better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluorodeoxyglucose (18F-FDG)
What this could lead to
If successful, this could lead to better, earlier detection of histiocytosis in children and more precise monitoring of the disease.
What could go wrong
This is a single-center, early-phase trial focused on imaging, not treatment. The results may not apply broadly, and the imaging agent carries standard radiation risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mother and Child Institute
RECRUITINGWarsaw, Mazovian, 01-211, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••